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Abstract
Introduction Increased versican expression has been
associated with local breast cancer invasiveness and a more
aggressive tumor phenotype. The cellular mechanisms are not
fully understood and this study evaluated versican G3 domain
with its EGF-like motifs in influencing tumor invasion and
metastasis.
Methods One recombinant construct was synthesized (a signal
peptide for product secretion and the versican G3 domain). The
construct was stably transfected into human breast carcinoma
MT-1 cells. Cell viability in vitro was evaluated in low serum and
serum starvation conditions. In vivo study of tumor growth was
evaluated in a nude mouse model. G3 effects on rodent vascular
endothelial cells were evaluated in vitro on cell survival,
apoptosis, migration, and vascular formation. The effects of
VEGF, fibronectin, and G3 on vascular formation were
examined. An intracardiac injection model of metastatic human
breast carcinoma tested the effect of G3 on distant bony and
soft tissue metastasis. Analysis of metastatic burden included
histology, radiographs, and micro-CT quantification of
osteolysis.
Results A greater viability of cancer cells was observed in low
serum and serum-free conditions in the presence of versican
G3. Larger subcutaneous tumors were obtained in the G3
group following tumor cell injection into CD1 mice. G3 induced
a greater degree of rodent vascular endothelial cell proliferation
and migration in vitro. Simultaneous presence of fibronectin,
VEGF, and G3 promoted endothelial cell migration in wound-
healing assays as compared to the treatments containing none,
one or two of these molecules. Systemic tumor burden to distant
bony and soft tissue metastatic sites was greater in the G3
group using the intracardiac injection metastatic model
Conclusion Versican G3 domain appears to be important in
local and systemic tumor invasiveness of human breast cancer.
Effects include enhancing cell viability, proliferation, migration
and enhancing local tumor growth. Potential effects on
angiogenesis include enhancing vascular endothelial
proliferation, migration, and vessel formation. The interactions
between tumor cells, surrounding stromal components and neo-
vascularization in breast cancer may include interactions with
VEGF and fibronectin. The propensity of versican G3 to
influence tumor invasion to bone and the mechanisms of G3
mediated osteolysis warrants ongoing studies.
Introduction
Versican is a large extracellular proteoglycan that is expressed
in a variety of tissues. It was originally isolated from human
fibroblasts and developing chicken limb buds during prechon-
drogenesis when primary mesenchymal cells differentiate into
chondrocytes [1-4]. This complex process involves cell divi-
sion, adhesion, migration, differentiation and production of
extracellular matrix (ECM) molecules. Similar to other mem-
bers of this large aggregating proteoglycan, common features
include the presence of N-terminal G1 and C-terminal G3
domains, and a large chondroitin sulfate side chain-bearing
sequence localized in the middle region. The G1 domain of
versican binds hyaluronan and the G3 domain consists of a
lectin-like carbohydrate recognition domain (CRD), and epi-
αVβ3 = αVβ3 integrin; β1 = β1 integrin; β3 = β3 integrin; CRD = carbohydrate recognition domain; ECM = extracellular matrix; EGF = epidermal 
growth factor; EGFR = epidermal growth factor receptor; hEGFR = vascular endothelial growth factor; micro-CT (μCT) = microcomputed 
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dermal growth factor (EGF)-like and complement-binding pro-
tein-like subdomains. Like other chondroitin sulfate
proteoglycans, versican has been reported to inhibit the adhe-
sion of cells to substrata [5]. Versican's activity on cell
adhesion varies and both anti-adhesive and adhesive proper-
ties have been reported [5-12]. Several studies support the
ability of versican to function as an anti-adhesive molecule with
activity that may reside in the G1 region [5-8]. Versican may
also repress focal contact formation and inhibit cell adhesion
[7]. Versican has been reported to interfere with the attach-
ment of cells to various extracellular matrix components such
as collagen I, fibronectin, and laminin [13]. It also appears that
versican can inhibit intercellular adhesion of normal as well as
malignant tumor cells [5,8,14]. The G3 domain of versican has
been observed to interact with β1 integrin in glioma cells acti-
vating FAK and promoting cell adhesion [9]. Versican also
binds to adhesion molecules including L and P selectin on the
surface of inflammatory leukocytes [10-12]. Alternate splicing
and different breakdown products of versican may in part
explain the molecules varying biologic activities in different
tissues.
Immunolocalization of versican in breast tumors, including infil-
trating ductal carcinoma, has been reported [15]. Of interest
is the observation that peripheral areas of infiltrating ductal
carcinoma have intense versican expression [15]. This sug-
gests that versican, a molecule with properties that influence
cell adhesion, may play an important role in tumor invasion
[6,8,14-16]. Extracellular PG-M/versican has been observed
to be elevated in a variety of human tumors including breast
carcinoma [15,17-21]. As a recognized modulator of cell
adhesion and motility for mesenchymal cells, increased versi-
can expression in malignant derivatives appears to contribute
towards a more aggressive phenotype [20,21]. Accumulation
of versican in breast and prostate tumors appears to be a neg-
ative predictor of survival [21,22].
The importance of versican G3 with its EGF-like motifs on
local tumor invasion has been demonstrated in other cancer
cell types [23-25]. The ability of a local tumor to grow beyond
a critical size appears to relate to the formation of vascular
stroma, the involvement of a variety of cell types including
malignant epithelial cells, surrounding stromal cells, and vas-
cular endothelium. The interaction between tumor cells, stro-
mal components, and growth factors that regulate cell division,
adhesion, migration and differential gene expression contrib-
ute to this growth. In cell culture versican is expressed only
when cells are actively proliferating. Once cells reach conflu-
ence, versican expression decreases [26]. Versican is also
highly expressed in some types of tumors where cells are
actively undergoing proliferation [15,17,18]. Versican's effect
on proliferation may be related to its C-terminal G3 domain
[6,16,27]. In astrocytoma, mechanisms appear to include ver-
sican G3 interactions with β1 integrin and angiogenic factor
VEGF [24,25].
Given the knowledge of systemic metastasis in breast cancer
to preferentially seed certain anatomic sites (i.e. bone), the
mechanisms of breast cancer invasiveness and metastasis in
particular to bone is also of interest. The potential role of anti-
adhesive molecules such as versican in systemic tumor inva-
siveness of breast carcinoma has not been extensively evalu-
ated. Versican is highly expressed during the development of
long bones in rats up to 6 weeks post partum. Immunoreactiv-
ity appears intense at the stage of woven bone and weaker in
lamellar bone [28]. Versican expression may be important dur-
ing the process of tumor bony invasion and subsequent
remodeling of bone that leads to osteolysis. We hypothesize
that the G3 domain of versican influences not only the local
tumor invasiveness in breast cancer but also systemic inva-
siveness of metastatic breast carcinoma to bone and soft tis-
sues. The present study evaluated this hypothesis in vitro and
in vivo in human MT-1 breast cancer cells.
Materials and methods
In vitro tumor cell viability
One recombinant construct was synthesized as described
previously [27]. In brief, the cDNAs of chicken versican G3
domain was subcloned in a mammalian expression vector
(pcDNA3). Shinomura et al. determined the entire cDNA
sequence of the core protein of chicken PG-M and the
deduced sequence revealed a high homology to the corre-
sponding domains of human versican [2]. A leading peptide of
link protein (nucleotides 1–180) was joined with versican G3
to facilitate secretion of the gene products. This leading pep-
tide possesses an epitope recognized by the monoclonal anti-
body 4B6. In addition, a His epitope was added to the C-
terminus of the constructs for staining and purification pur-
poses. The G3 construct and a control vector were stably
transfected into human breast carcinoma MT-1 cells using
Lipofectamine 2000. The MT-1 cells used in the study were
provided by Dr O Engenbraaten (Norwegian Radium Hospital,
Oslo, Norway) [29]. Recombinant proteins containing C-termi-
nal His-tag in the culture media were subjected to purification
using Ni-NTA affinity columns under native directions. The
purity of G3 peptides was confirmed by analysis on SDS-
PAGE and western blots probed with monoclonal antibody
4B6 recognizing an epitope on the leading peptide.
Human MT-1 cells stably transfected with the G3 construct or
the control vector were cultured at a density of 1 × 105 cells/
ml/well on 12-well tissue culture plates in RPMI-1640 media
(Life Technologies, Inc. Rockville, Maryland) supplemented
with 10% fetal bovine serum (Seromed Inc., Berlin, Germany).
Cells were cultured at 37°C in a humidified incubator contain-
ing 5% CO2 for two days. On day 3, culture media was
changed to either serum-free media or media containing 1%
fetal bovine serum. Cell numbers were counted on days 4, 5,
6, and 7. The experiment was repeated in triplicate for each
tumor cell group and culture media was evaluated for consist-
ent construct expression. Statistical analysis was performedAvailable online http://breast-cancer-research.com/content/9/4/R47
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by non-parametric tests for two independent samples compar-
ing cell viability at the time-points indicated previously. Statis-
tical significance was set at p < 0.05.
In vivo G3 effects on local tumor growth
A rodent model of human MT-1 cells inoculated into 6-week
old CD1 strain nude mice was used. Following appropriate
institutional animal care committee approval, 5 × 106 cells
were inoculated subcutaneously into the dorsal paraspinal tis-
sues. Animals were randomized to either human MT-1 cells
containing either versican G3 domain (G3) or the control vec-
tor. Human breast cancer cells MT-1 were cultured in RPMI
media at 37°C with 5% CO2. At 70% to 80% subconfluency,
the cells were given fresh media 24 h before inoculation into
the mice. Cell viability was determined by trypan blue exclu-
sion, and cells were suspended with greater than 95% viability
without cell clumping. We then injected 5 × 106 cells in 0.2 mL
serum-free RPMI media into the dorsal subcutaneous parasp-
inal region of each rat using a 1 mL syringe with a 26 G needle.
Animals were recovered from anesthesia and permitted ad lib
cage activity. Tumors were measured weekly thereafter. Tumor
volume (V) was estimated using a caliper by measuring the
maximal length (L) and width (W), where V = (L × W2)/2. Sta-
tistical analysis was performed using non-parametric tests for
two independent samples with statistical significance set at p
< 0.05.
Six weeks after injection, animals were killed by CO2 inhalation
for further analysis. At necroscopy, tumors were excised, lysed
and proteins analyzed by Western blot probed with mono-
clonal antibody 4B6 that recognizes an epitope at the N-termi-
nal G3 domain [14]. In brief, the lysates were sonicated and
cleared by centrifugation. The supernatant was subjected to
SDS-PAGE and electroblotted onto a nitrocellulose mem-
brane (Bio-Rad) in 1 × TG buffer (Amresco) containing 20%
methanol. The membrane was blocked in TBST (10 mM Tris-
Cl, pH 8.0, 150 mM NaCl, 0.05% Tween 20) containing 10%
non-fat dry milk powder (TBSTM) for 1 h at room temperature,
and then incubated with primary antibodies at 4°C overnight.
The membranes were washed with TBST (3 × 30 min) and
then incubated with appropriate horseradish peroxidase-con-
jugated secondary antibodies in TBSTM for 1 h. After washing
as above, the bound antibodies were visualized with an ECL
kit according to the manufacturer's instructions (Amersham).
In vitro effects of G3 on endothelial cells
For these experiments, rat endothelial cells (cell line Ypen-1;
CRL-222 immortalized by Adenovirus-12 SV40 hybrid virus;
American Type Culture Collection, Rockville, Maryland) were
used. For the cell proliferation assay, endothelial cells were
seeded to 12-well tissue culture plates at a density of 1 × 104
cells/well in IMDM containing 5% FBS and maintained at
37°C overnight. After 12–16 h, culture medium was removed
and the cultures were washed with PBS, followed by addition
of 1% FBS/IMDM that had been pre-incubated (48 h) with G3
or vector transfected cells. Three days after medium change,
endothelial cells were harvested and the cell number was
determined with a Coulter counter.
For the cell migration (wound-healing) assay, endothelial cells
were seeded to six-well tissue culture plates at a density of 3
× 105 cells/well in IMDM containing 5% FBS and the cultures
were maintained until they reached 95% confluence. The cul-
tures were wounded by scoring with sterile micropipette tips,
then washed and fed with 1% FBS/IMDM, which had been
pre-incubated (48 h) with G3 or vector transfected cells. After
36 h, the cultures were photographed using a low-magnifica-
tion microscope. As well, the wounded cultures were incu-
bated with medium containing VEGF and fibronectin at the
desired concentrations, followed by photography.
For the cell survival and apoptosis assay, endothelial cells (2
× 105 cells) were seeded on six-well tissue culture plates to
obtain monolayer cultures, and culture medium was replaced
with 1% FBS/IMDM, which had been pre-incubated (5 days)
with vector or G3 transfected cells. The cultures were main-
tained at 37°C for 36–48 h. Detached cells were removed and
the cultures were washed. The cultures were examined and
photographed under a light microscope. Adherent cells were
harvested with trypsin/EDTA and the cell number was
counted.
After medium change, the cultures were also maintained for
24 h. Cell morphology was examined under a light micro-
scope. Cells adhered to the plates and detached cells in the
medium were harvested and combined. Total DNA was pre-
pared, which included those released to the cytoplasm due to
fragmentation and those staying in the nucleus, and analyzed
on agarose gel to detect DNA fragmentation using a previ-
ously reported technique [30].
To evaluate the formation of vessel-like structures, endothelial
cells (2 × 105 cells) were inoculated on six-well tissue culture
plates to obtain monolayer cultures, and culture medium was
replaced with IMDM that had been pre-incubated (48 h) with
vector- or G3 transfected cells and that contained 0.5% or 1%
FBS. The cultures were maintained at 37°C for 3–4 days to
assess the effects of G3 containing medium.
In vivo G3 effects on metastasis
A rodent intracardiac injection metastatic osteolytic model of
human breast carcinoma was used [31]. Following institutional
animal care and use committee approval, vertebral metastases
were generated by the injection of human breast cancer carci-
noma cells (MT-1 – G3 or vector control) into nude rats (rnu/
rnu; Harlan Spraque Dawley, IN, USA). Human MT-1 cells
expressing versican G3 or vector control constructs were cul-
tured at a density of 1.2 × 106 cells/ml in 175 cm2 flasks in
RPMI-1640 media (Life Technologies, Inc. Rockville, MD,
USA) supplemented with 10% fetal bovine serum (SeromedBreast Cancer Research    Vol 9 No 4    Yee et al.
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Inc., Berlin, Germany) and 1 mg/ml Geneticin® (Invitrogen,
Burlington, Ontario, Canada). A total of 15 5–7 weeks old
female rats were randomly allocated to either the versican G3
experimental group or vector control group. Each animal was
injected with 2 × 106 cells in 200 μl RPMI-1640 media into the
left heart ventricle using a 1 ml syringe with a 25 G needle
under general anaesthesia (2% isofluorane/2 L O2/min). Pul-
satile blood within the needle cone confirmed the correct posi-
tion of the needle. The animals were immediately recovered
and returned to their cages with free access to food and water.
The animals were clinically assessed daily and their weight
was recorded once a week. Rats were killed at 24 days or at
acceptable tumour endpoints for animal care. The rats were
killed with a barbiturate overdose (120 mg/kg Euthanol®,
Bimeda-MTC, Cambridge, Canada).
For analysis, fine detail radiographs were taken (Model MX-20;
Faxitron X-ray Corp., Wheeling, IL, USA) of murine appendic-
ular bones. Digital images of scapular osteolysis were ana-
lyzed using Image-Pro Plus (Media Cybernetics, Silver Spring,
MD, USA) and an areal (mm2) quantification of osteolysis per-
formed comparing experimental to control groups. Necros-
copy was performed and solid organs were evaluated for
macroscopic tumors. In addition, histological evaluation of
tumour burden was performed on bony sites including the
humeri, femora, lumbar spine and solid organ sites including
the brain, lung, liver, spleen and kidney. The slides were
stained with haematoxylin and eosin as well as with an anti-
body to human EGFR (Zymed EGFr Kit #28-0005; Zymed
Laboratories Inc., San Francisco, CA, USA). This antibody
does not crossreact with rat tissue thereby facilitating the
identification of human cells within murine vertebrae. The lum-
bar vertebrae (L1–L4) of experimental and control (vector) ani-
mals underwent micro-CT scanning for volumetric
measurements of tumour burden prior to histology analyses
(resolution: 34.7 μm × 34.7 μm × 34.7 μm/voxel). Vertebral
bodies of each rat were individually analyzed. The outer verte-
bral bodies were segmented using a semi-automated level set
method. The pedical–vertebral body interface and greater
region of interest was manually defined with a flattened cylin-
der. The exterior of the vertebral body cortex was automatically
detected with a level set method. (ITK, Bethesda, MD, USA).
Mean intensity, standard deviation of intensity and median
intensity within the vertebral body were calculated using Amira
software (Amira v. 3.1.1, Mercury Computer Systems,
Chelmsford, MA, USA). Within the vertebral body, bone and
marrow were distinguished using a threshold of 1000 Houns-
field Units (HU) and volumes were calculated. Stereological
quantities were calculated using the described volumetric
analysis and triangulated surface data. Histomorphometry was
performed using Image Scope (Aperio Technologies Inc.,
Vista, CA, USA). Statistical analyses were performed using
non-parametric analysis for two independent samples and
analysis of variance for repeated measurements of animal
weight over time. Statistical significance level was set at p <
0.05.
Results
G3 expression in breast cancer cells
Morphologically, cells in the G3 transfected group appeared
more elongated in vitro when compared to the predominant
cuboid appearance of cells in the vector control group sug-
gesting an enhancement of cell elongation by the G3 product
(Figure 1a). The expression of G3 in the cell lysate and culture
media of MT-1 cells transfected with the G3 construct con-
taining EGF-like motifs is depicted in Figure 1b and is con-
trasted to the vector control group. Greater tumor cell viability
was observed in serum-free and 1% FBS culture conditions
for the G3 experimental group when compared to the vector
control group (p < 0.05 days 5, 6, and 7; Figure 1c and 1d).
G3 mediated tumor growth properties in vivo
In vivo, rodents inoculated subcutaneously with MT-1 cells
transfected with the G3 construct containing EGF-like motifs
grew larger local tumors when compared to the vector control
group (Figure 2a and 2b, mean volume +/- SD in experimental
group vs vector controls, p < 0.01). This was consistent with
the observation of increased versican G3 expression as
assessed by immunoblotting in the experimental group follow-
ing tumor tissue harvest when compared to the vector control
group (Figure 2c).
G3 mediated effects on endothelial cells
We studied how G3 affected vessel formation in vitro using rat
endothelial cells as a culture model. When endothelial cultures
were treated with medium obtained from G3 transfected cells,
the cultures formed vessel-like structures (Figure 3). The
endothelial cultures were treated with 1% FBS-containing
medium that had been pre-incubated (5 days) with G3 and
vector-transfected cells. G3 containing medium was found to
promote cell viability (Figure 4a), and quantitative analysis indi-
cated that the difference between G3 and vector-transfected
cells was very significant (Figure 4b; mean number/field ±
SD). To examine how these cells died and detached from the
plates, cell morphology was monitored carefully. We observed
that 24 h after medium change, cells treated with control
medium underwent apoptosis, while cells treated with G3
containing medium grew normally (Figure 4c). Evidence of
DNA laddering further confirmed apoptosis in the cultures
treated with medium from vector-transfected cells (Figure 4d).
G3 effects on endothelial cell migration with and without 
the presences of VEGF and fibronectin
In a wound-healing assay, treatment with G3 containing
medium greatly enhanced endothelial cell migration to the
wounding areas, as compared to control medium (Figure 4e).
Our results demonstrated the effects of G3 on endothelial cell
activities that are known to be relevant and may contribute to
angiogenesis. Combinations of fibronectin, VEGF and purifiedAvailable online http://breast-cancer-research.com/content/9/4/R47
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G3 were tested. In all cases, the simultaneous presence of
fibronectin, VEGF and purified G3 promoted endothelial cell
migration in wound-healing assays as compared to the
treatments containing none, one or two of these molecules
(Figure 5).
In vivo G3 effects on systemic metastasis
All rats (15/15) developed metastases in bone and solid
organs. Animal weight loss was observed as early as 2–3
weeks following intra-cardiac tumor cell injection. There
appeared to be a trend to a more progressive weight loss pat-
tern in the versican G3 group following tumor cell injection,
however, the differences were statistically not significant (p =
0.07). At necroscopy, macroscopic tumor burden in soft tis-
sue metastatic sites was greater for the versican G3 group. All
animals developed brain and lung metastasis in the versican
G3 group when compared to 73% for brain and 27% for lung
in the vector control group (p < 0.05). Ovarian and renal
tumors were also more prevalent in the G3 group (67%) when
compared to 27% of control animals (p < 0.05). The macro-
scopic size of the observed ovarian metastases in the G3
group was larger when compared to the vector group, a find-
ing that was confirmed by subsequent histological evaluation.
Appendicular osteolysis was observed by 3 weeks using fine
detail radiography. The area of osteolysis was significantly
higher in the experimental group when compared to the con-
trol group (p = 0.002) (Scapular osteolysis shown in figure 6).
Vertebral osteolysis as quantified by μCT imaging was signifi-
cantly greater in the G3 experimental group when compared
to the vector-control group. As a result of osteolysis, remaining
bone volume/total vertebral volume was 0.69 ± 0.07 (mean ±
SD) in the control group and 0.58 ± 0.08 (mean ± SD) in the
G3 group; p = 0.003. Concordantly, a greater tumor burden
as reflected by histologic staining for hEGFr was observed in
harvested lumbar spine of versican G3 rats. The mean ± SD
percentage hEGFr staining positivity was 10.0 ± 10.5 control
group, 23.7 ± 7.2 G3 group, p = 0.004) (Figure 7). Metas-
tases to bone were confirmed histologically and radiologically
in all animals although tumor burden was greater for the G3
group when compared to the vector control group.
Discussion
The results of the present study indicate that the G3 domain
of versican influences breast cancer tumor cell adhesion,
migration, proliferation and metastatic tumor burden. A greater
viability of human MT-1 breast cancer cells in vitro was
Figure 1
In vitro MT-1 cell viability In vitro MT-1 cell viability. The morphology of human MT-1 cells in vitro, expression of G3 in cell lysate and culture media, and tumor cell viability in 
serum-free and 1% FBS culture conditions for the G3 experimental group are compared to control. (a) Morphologically, cells in the MT-1 G3-trans-
fected MT-1 cells appeared more elongated in vitro when compared to the predominant cuboid appearance of cells in the vector control group. (b) 
The expression of G3 in the cell lysate and culture media of MT-1 cells is demonstrated and is contrasted to the vector control group. (c) A greater 
tumor cell viability (mean cell number + SD) was observed in serum-free and (d) 1% FBS culture conditions for the G3 experimental group as com-
pared with the vector control group (p < 0.05 days 5,6, and 7).Breast Cancer Research    Vol 9 No 4    Yee et al.
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observed in low-serum or serum-free conditions. This was also
consistent with the observations of a greater degree of local
tumor growth when evaluated in the in vivo rodent model. On
average, local tumors were three- to fourfold larger in the G3
experimental animals when compared to vector control
animals 6 weeks following subcutaneous tumor cell injection.
Consistent with the observation of greater local tumor growth,
the G3 domain of versican also influences the development of
distal metastasis to bone and soft tissue. Athymic rats injected
with versican G3 transfected human breast carcinoma cells
(MT-1) were observed to demonstrate a greater systemic
tumor burden than animals injected with control cells.
Although all animals in the study developed systemic metasta-
sis the number and size of the metastases were larger in the
versican G3 group when compared to the vector control
group. Bony tumor burden as quantified radiologically was
greater for the experimental G3 group.
Extracellular matrices that express high amounts of versican
may function as modulators of cell proliferation and migration
[32]. Versican expression has been shown to be a predictor of
breast cancer survival in women and increased versican
expression in the peri-tumoral matrix is correlated with a higher
risk of cancer relapse [21]. A significant correlation between
tumor grade and degree of versican expression has also been
observed in canine colonic adenocarcinomas [33]. The
expression of versican by tumor cells themselves appears to
vary. Versican expression has been observed in both tumor
and stromal cells although the relative extent varies amongst
different cancer cell types. The direct expression of versican
by tumor cells is variable with a greater expression being asso-
ciated with highly malignant tumors [34]. The expression of
versican by tumor cells appears to relate to higher mitotic
activity and a reflection of cell proliferation [34]. Versican
mediated cancerous growth appears dependent on the close
interactions between tumor cells and its surrounding stromal
components. In breast cancer, there does appears to be a
greater degree of versican localization in interstitial stromal tis-
sue within tumor cell nests versus that observed in either the
tumor cells themselves or in stromal tissue of adjacent non-
malignant areas of breast tissue [15,21]. A limitation of the int-
racardiac injection metastatic model used in the present study
is that it bypasses the step of initial establishment of a local
tumor with secondary circulatory seeding. A spontaneous
mouse mammary model of metastasis may be considered
more reflection of the physiologic process of invasion and
metastasis however the cells utilized are not of human origin.
In vitro studies using conditioned media from breast cancer
cell lines are able to upregulate versican expression of cancer
derived and non-cancer derived mammary fibroblasts without
an observed difference in basal level of versican synthesis or
the degree of stimulation observed between the two fibroblast
groups [21]. The peripheral regions surrounding a tumor
appear to have a greater versican expression and the path-
ways involved in versican-mediated cancerous growth war-
rants ongoing study.
There is increasing knowledge on the pivotal role of epidermal
growth factor receptor (EGFR) together with HER2 in breast
carcinoma and how it may influence downstream signal trans-
duction pathways that regulate cell survival and proliferation
[35-38]. The presence of two EGF-like motifs in versican G3
given the increasing importance known clinically regarding the
role of EGF receptors in invasive breast carcinoma is of inter-
est. Certain breast carcinoma cell lines (e.g. MDA-MB-231)
have been reported to over express the receptor for EGF [39].
The breast cancer cell line (MT-1) used in the present study
also possess a high cell surface expression of the EGF recep-
tor [29]. Interaction of the EGFR and versican has been dem-
onstrated for transfected astrocytoma U87 cells [25,40]. In
addition, versican binds to hyaluronan through its tandem
repeats. Versican–hyaluronan complexes increases viscoelas-
ticity around the cells to support cell-shape changes neces-
sary for proliferation and migration [41,42]. It has been shown
that hyaluronan production is increased at sites of cell prolifer-
ation, tissue remodeling and tumor cell invasion [40].
Figure 2
Versican mediated in vivo local tumor growth Versican mediated in vivo local tumor growth. Greater tumor growth 
(mean volume mm3 + SD) was observed in the experimental group of 
animals inoculated with G3 expressing MT-1 cells. (a, b) Animal inocu-
lated with G3-transfected cells grew larger local tumors when com-
pared to the control group (p < 0.05). (c) This was consistent with the 
observation of increased versican G3 expression as assessed by immu-
noblotting in the experimental group following tumor tissue harvest 
when compared to the vector control group.Available online http://breast-cancer-research.com/content/9/4/R47
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Neoangiogenesis, the new formation of blood vessels is asso-
ciated with endothelial cell proliferation, migration, and forma-
tion of new capillaries is a response to the increased demand
of tumor tissue for oxygen and nutrients. Although no in vivo
assay for angiogenesis was performed in the present study,
we observed in vitro that versican G3 influenced vascular
endothelial proliferation through mechanisms that include
apoptosis. In our study, a greater degree of DNA laddering
was observed in the vector control group (Figure 4d) than in
the versican G3 experimental group. The migration of rat
endothelial cells across a gap in vitro also appeared to be
greater in the presence of G3 conditioned media. The mecha-
nisms of versican interaction with other cell and extracellular
matrix components appear to include cell surface integrins (i.e.
β1 integrin), fibronectin, and angiogenic factors (i.e. VEGF)
[9,24]. It has been reported that PG-M/versican prepared from
chicken fibroblasts and versican-like proteoglycans prepared
from human sciatic nerve bind to fibronectin [13,43].
Fibronectin also binds VEGF and regulates endothelial cell
activities [44]. We examined if the presence of these mole-
cules affected endothelial cell activities. Combinations of
fibronectin, VEGF and purified G3 were tested. In all cases,
the simultaneous presence of fibronectin, VEGF and purified
G3 promoted endothelial cell migration in wound-healing
assays as compared to the treatments containing none, one or
two of these molecules (Figure 8).
In this study, metastases developed mainly in tissues where
versican is still expressed in human adults and rat tissue [45].
A greater tumor burden was observed in brain, lung, ovary, kid-
ney and bone in G3 rats when compared to vector control.
Given the knowledge of systemic metastasis in breast cancer
to preferentially seed certain anatomic sites notably bone, the
relationship of breast cancer and versican in bone is of inter-
est. Engebraaten et al. observed site-specific establishment of
metastases dependant on breast cancer cell line evaluated
noting that MT-1 cells had a predilection for bony metastasis
when compared to solid organ metastases using MA-11 cells
Figure 3
The formation of vessel-like structures in G3-expressing cells The formation of vessel-like structures in G3-expressing cells. Culture medium in subconfluent endothelial cells was replaced with 0.5% or 1% FBS/
culture medium that had been pre-incubated with G3- and vector-transfected cells for 48 h. Three (3 d) or four (4 d) days after medium change, cul-
tures treated with G3-containing medium formed clear vessel-like structures as compared to the vector control. The scale bar depicted represents 
250 μm.Breast Cancer Research    Vol 9 No 4    Yee et al.
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[29]. The present study corroborated this site specificity with
bony metastasis occurring in all rats although the tumor bur-
den was greater for the G3 experimental group. The role of
versican in bone is less well characterized than its expression
and function in other soft connective tissues. Nakamura et al.
evaluated the expression of versican and ADAMTS 1,4,5 (a
family of extracellular proteases, which are implicated in cleav-
ing the protein versican) in rat bone development [28]. Versi-
can appears highly expressed during the development of long
bones in rats up to 6 weeks post partum. Immunoreactivity
appears intense at the stage of immature woven bone and
weaker in mature lamellar bone [28]. Versican mRNA was
prominent in osteoblasts and corresponded to localization of
the protein. The temporal and spatial mRNA expression pat-
tern of ADAMTS 1, 4, and 5 followed that observed for versi-
can. Thus, during bone development woven bone rich in
versican alters into lamellar bone containing little versican. Ver-
sican expression may also be important during the process of
tumor bony invasion and subsequent remodeling of bone that
leads to osteolysis with a resultant loss in mature organized
bony micro-architecture. The propensity of versican G3 to
Figure 4
Effect of G3 on endothelial cells Effect of G3 on endothelial cells. (a) G3-containing medium enhances 
cell attachment and promotes greater cell viability. Culture medium in 
subconfluent endothelial cell cultures was replaced with 1% FBS/
medium that had been preincubated with G3- or vector-transfected 
cells for 5 days. Two days after medium replacement, spent medium 
from vector-transfected cells promoted the detachment of cells from 
plates while spent medium from G3-transfected cells did not. (b) After 
cell detachment, cultures were washed, and the adherent cells were 
harvested and counted (mean number/field + SD). The difference in 
cell viability between cultures treated with medium from G3- and vec-
tor-transfected cells was significant (p < 0.01). This figure also demon-
strates that G3-containing medium enhances cell proliferation and 
reduces cell apoptosis. (c) One day after medium change, cells treated 
with medium from vector-transfected cells underwent apoptosis, while 
cells treated with G3-containing medium grew normally. (d) DNA was 
prepared from cytoplasmic and nuclear fractions and subjected to aga-
rose gel electrophoresis. DNA laddering was detected in cells treated 
with medium from vector-transfected cells.
Figure 5
Endothelial cell migration Endothelial cell migration. G3-containing medium enhances endothelial 
cell migration 48 h following gap formation (a). Monolayer endothelial 
cell cultures were wounded (0 h) by micro-tips and washed with PBS, 
followed by addition of culture medium pre-incubated with G3- and 
vector-transfected cells. Addition of G3-containing medium enhanced 
endothelial cell migration to the wounding areas. Endothelial cell migra-
tion is enhanced in the presence of purified G3, fibronectin (FN) and 
VEGF (b). Endothelial cells were seeded on 12-well tissue culture 
plates. The cultures were wounded with micro-tips (before) and 
washed, and fibronectin, VEGF and purified G3 were added individu-
ally or in combination as indicated. In the presence of all three mole-
cules, cells exhibited enhanced migratory capacity. Medium represents 
culture media in the absence of G3, VEGF, and FN.Available online http://breast-cancer-research.com/content/9/4/R47
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influence tumor invasion to bone and the mechanisms of ver-
sican G3 mediated osteolysis warrants ongoing study. With
the known interactions between versican G3 and β1 integrin
in other cancer cell types and the increasing knowledge of
several β3 integrin-expressing cell populations including oste-
olasts in breast cancer tumor progression, the known interac-
tion between versican G3 and integrin receptors such as
αVβ3 in bone may increase our understanding towards tumor
mediated chemotactic and haptotactic migration towards
bone factors [25,46].
Conclusion
In summary, versican is implicated in local tumor invasiveness
in human breast carcinoma. The present study suggests a
potential significant role of the G3 domain of versican with its
EGF-like motif in influencing tumor cell viability, proliferation,
and local tumor growth. These effects also include potential
effects on endothelial cells that are implicated in neo-angio-
genesis. Versican G3 also influences systemic metastasis in a
murine model of metastatic human breast carcinoma. The pro-
pensity of versican G3 to influence tumor invasion to bone and
Figure 6
Appendicular osteolysis Appendicular osteolysis. Faxitron images of rat shoulder and proximal 
humerus specimens as well as femura and proximal tibia of vector con-
trol rats (a, c) and MT-1-G3 rats (b, d). Mean + SD percent osteolysis 
within the shoulder blade was 8.1 + 8.2 in the control group versus 
34.7 + 13.8 in the G3 group (e).
Figure 7
Lumbar vertebral histology Lumbar vertebral histology. Decalcified lumbar vertebrae section 
stained with human EGFR antibody and anti-versican G3 domain anti-
body 4B6 of a rat inoculated with (a, b) G3-transfected MT-1 cells 
when compared to lesser tumor burden observed in a representative 
control animal (c).Breast Cancer Research    Vol 9 No 4    Yee et al.
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the mechanisms of versican G3 mediated osteolysis warrants
ongoing study.
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